Yew siRNA new drug technology

Chair Prof. Jiang Zhi Hong’s Research Team-Taxus chinensis siRNA new drug techniques

The “Taxus chinensis siRNA new drug techniques”, developed by the research team of Chair Prof. Zhihong Jiang, Vice President of M.U.S.T. and Director of the SKL of Quality Research in Chinese Medicines, constitutes a combo of therapeutics and drugs used to treat cancer. The Increasepharm (HK) Limited acquired the Intellectual Property (IP) rights of the project for a technology transfer fee of RMB 50 million, plus a 2% royalty on sales during the launch phase of the product.

The Above figure represent the Chair Professor Jiang, zhi-hong, Director of SKL; below figure represent the RNA omics platform facilitates the discovery of yew siRNA molecules.